SEC Comment Letter 0000000000-26-003830 to AN2 Therapeutics, Inc. (ANTX)
AN2 Therapeutics, Inc.
Date: April 15, 2026 · CIK: 0001880438 · Accession: 0000000000-26-003830
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294956
Letter
Re: AN2 Therapeutics, Inc. Registration Statement on Form S-3 Filed April 9, 2026 File No. 333-294956 Dear Eric Easom:
April 15, 2026
Eric Easom President and Chief Executive Officer AN2 Therapeutics, Inc. 1300 El Camino Real, Suite 100 Menlo Park, California 94025
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Richard Kim
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 15, 2026 Eric Easom President and Chief Executive Officer AN2 Therapeutics, Inc. 1300 El Camino Real, Suite 100 Menlo Park, California 94025 Re: AN2 Therapeutics, Inc. Registration Statement on Form S-3 Filed April 9, 2026 File No. 333-294956 Dear Eric Easom: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Richard Kim </TEXT> </DOCUMENT>